DDInter1398 DDInter899
Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Pasireotide {u} (Compound) resembles {v} (Compound) Terlipressin
Pasireotide {u} (Compound) binds {v} (Gene) SSTR5
Pasireotide {u} (Compound) is included by {v} (Pharmacologic Class) Somatostatin Receptor Agonists
Pasireotide {u} (Compound) causes {v} (Side Effect) Abdominal pain
Pasireotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Pasireotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metoprolol
Pasireotide {u} may lead to a major life threatening interaction when taken with {v} Protriptyline
Pasireotide {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Pasireotide (Compound) resembles Terlipressin (Compound)
Pasireotide (Compound) binds SSTR5 (Gene)
Pasireotide (Compound) is included by Somatostatin Receptor Agonists (Pharmacologic Class)
Pasireotide (Compound) causes Abdominal pain (Side Effect)
Pasireotide may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Pasireotide may cause a minor interaction that can limit clinical effects when taken with Doravirine
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol
Pasireotide may lead to a major life threatening interaction when taken with Protriptyline
Pasireotide may lead to a major life threatening interaction when taken with Fingolimod